Entrada Therapeutics · 7 hours ago
Associate Director, Clinical Scientist (CONSULTANT)
Boston, MA
Full-time
Hybrid
Senior Level, Lead/Staff, Director/Executive
6+ years expEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients through innovative medicines. The Associate Director, Clinical Scientist will lead data review and support clinical trials in Duchenne muscular dystrophy, utilizing Entrada’s unique EEV technology.
BiotechnologyEmergency MedicineGeneticsHealth CareMedical
Responsibilities
Support interpretation of clinical data to generate high quality summaries and insights to support regulatory filings, publications and scientific communications
Collaborate cross-functionally with Medical Directors, Clinical Operations, Data Management, Biostatistics, and Business Operations to help drive execution across clinical phases
In partnership with Medical Directors, lead or support the authoring of selected sections of clinical study reports
Support real-time data review, identify trends in safety and efficacy data and assessing protocol compliance including protocol deviation reviews, escalating to Medical Monitor(s) where appropriate
Identify scientific and/or clinical quality issues to discuss with PI and study sites, partnering with study team and GCP quality team members for escalations as needed
Consultant on the design of study-specific case report form (CRF) and author study-specific sections of the CRF completion guidelines, ensuring CRFs are aligned with study requirements during user acceptance testing
Perform safety and efficacy reviews in preparation for DMC, in conjunction with Medical Director and other internal stakeholders, analyzing trends within and across programs
Collaborate with Business Operations and Data Management to lead development and innovation of department clinical data technology access, retention, and visualization strategy, to support trend identification across programs
Support innovation and strategy for the integration of new tools and technologies into phase 1-3 clinical studies
Qualification
Required
Ph.D., PharmD, MD, Nursing, or Clinical Master's degree in a scientifically relevant field, with 6 + years of clinical development experience within the biotechnology or pharmaceutical industry
Proven understanding of clinical development processes to serve as subject matter expert for phase 1-3 clinical studies
Previous experience identifying trends and setting risk mitigation strategies in partnership with Medical teams within clinical studies
Demonstrated experience in the design and execution of clinical trials and a strong understanding of GCP/ICH guidelines and regulatory expectations
Skilled in Microsoft suite as well as innovative data review tools (ie. patient profiles, report generating tools)
Self-motivated, demonstrated success in delivering assigned tasks according to timelines
Demonstrated history of creative problem-solving and learning ability
Ability to interpret complex data and communicate clearly with both scientific and non-scientific stakeholders
Strong data analysis, data visualization and communication skills, with ability to write clear, accurate and concise documents, construct informative figures, and present to diverse audiences
Desire to work in an innovative and collaborative, fast paced, mission driven environment, taking on new challenges with an adaptable mindset
Preferred
Experience in rare disease and/or neuromuscular disease is strongly preferred
Company
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
51-200 employees
H1B Sponsorship
Entrada Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (7)
2024 (14)
2023 (4)
2022 (6)
2021 (1)
2020 (1)
Funding
Current Stage
Public CompanyTotal Funding
$301.6MKey Investors
Wellington Management
2024-06-24Post Ipo Equity· $100M
2022-12-08Post Ipo Equity· $26M
2021-10-29IPO
Leadership Team
Dipal Doshi
Chief Executive Officer
Leo Qian
Co-Founder
Recent News
BioWorld Financial Watch
2026-01-11
2025-12-17
Company data provided by crunchbase